secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008301
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Q4 2022 revenue $10.2M (-9% YoY); net loss narrows to $2.5M from $3.9M
-----------------------------------------------------------------------------

- Q4 2022 total revenue $10.2M, down 9% from $11.2M in Q4 2021 due to lower South Korea procedure revenue.
- Net loss Q4 2022: $2.5M ($0.24 per share) vs $3.9M ($0.41) in Q4 2021; Adjusted EBITDA improved to ($0.065M) from ($1.6M).
- Installed ten ALLY Adaptive Cataract Treatment Systems in 2022; contracts signed for six more systems, installations expected H1 2023.
- SG&A expenses rose 24% to $7.2M, driven by ALLY promotion; R&D fell 53% to $1.6M as ALLY development costs normalized.
- CEO reports positive surgeon feedback: ALLY cuts 1-1.5 hours from surgical day, supports faster case volume.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/0000950170-23-008301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/lnsr-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer